EXAMINE THIS REPORT ON HEMGENIX

Range of qualified clients: CDEC reviewed the uncertainty in the number of sufferers with moderately extreme to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some individuals who're labeled as owning delicate or average disease might have a intense bleeding phenotype,